Anaplastic thyroid carcinoma (ATC) is a very rare neoplasm with an aggressive course. The prognosis has not changed in the last decades and the median survival does not exceed six months. Only few patients with incidental limited ATC will be cured. Different therapeutic options have been explored but the results are disappointing. At present, new drugs and new timing for proper treatment are under investigation. In this short review we have summarized these recent developments.
GillilandF.D., HuntW.C., MorrisD.M., KeyC.R.: Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer, 79: 564–573, 1997.
NilssonO., LindebergJ., ZedeniusJ., EkmanE., TennevallJ., BlomgrenH., GrimeliusL., LundellG., WallingG.: Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. Word J Surg, 22: 725–730, 1998.
4.
McIverB., HayI.D., GiuffridaD., DvorakC.E., GrantC.S., ThompsonG.B., van HeerdenM.D., GoellnerJ.R.: Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery, 130: 1028–1034, 2001.
5.
SugitaniI., KasaiN., FujimotoY., YanagisawaA.: Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg, 25: 617–622, 2001.
6.
KobayashiA., AsakawaH., UmeshitaK., TakedaT., MaruyanaH., MatsuzukaF., MondenM.: Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck, 18: 36–41, 1996.
7.
SuginoK., ItoK., MimuraT., NagahamaM., FukunariN., KuboA., IwasakiH., ItoK.: The important role of operations in the management of anaplastic thyroid carcinoma. A clinicopathologic study of 121 cases. Surgery, 131: 245–248, 2002.
8.
VenkateshY.S., OrdonezN.G., SchultzP.N., HickeyR.C., GoeffertH., SamaanM.A.: Anaplastic carcinoma of the thyroid. Cancer, 66: 321–330, 1990.
9.
HaighP.I., ItuarteP.H., WuH.S., TreselerP.A., PosnerM.D., QuiveryJ.M., DuhQ.Y., ClarkO.H.: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer, 23: 1252–1261, 2001.
10.
JuniorE.J., PaulJ., ReddN.S.: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol, 18: 83–88, 1992.
11.
BesicN., AuerspergM., Us-KrasovecM., GolouhR., Frkovic-GrazioS., VodnikA.: Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol, 27: 260–264, 2001.
12.
PierieJ.P., MuzikanskyA., GazR.D., FaquinW.C., OttM.J.: The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol, 9: 57–64, 2002.
AinK.B., EgorinM.J., DeSimoneP.A.: Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid, 10: 587–594, 2000.
17.
XuG., PanJ., MartinC., YeungJ.: Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metabol, 86: 1769–1777, 2001.
18.
VoigtW., BulankinT., MullerC., SchoeberA., GrotheyA., Hoang-Vu, SchmollH.J.: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res, 6: 2087–2093, 2000.
